Startups

TTTTT

Our startups

Be inspired. Search our startups.

Filter
Diamond Winners
2014 Boston Diamond Winner

SQZ Biotech’s CellSqueeze enables the delivery of molecules into cells by a gentle squeezing. It was invented at MIT in the labs of Prof. Bob Langer and Prof. Klavs Jensen. It's shown 10-100x improvement relative to competing technologies for major unmet needs: primary cells and non-nucleid acid molecules (e.g. proteins). We own the exclusive license from MIT to any application. We started in the research market but plan to pursue higher impact applications (e.g. therapeutics) in the future.

Gold Winners
2017 Boston Gold Winner

W8X helps athletes get the most out of their workout. Inspired by robotics, we developed a training system that automatically changes resistance to adapt to a user's needs. The system has the size of a shoebox but provides safer and more effective training than traditional equipment. Controlled through an app, the system tracks metrics and provides valuable feedback. We work with leading coaches and professional athletes to reinvent strength training for the gym and for the home.
*fundraising

2017 Boston Gold Winner

Recent clinical studies proved that consistently introducing food allergens to infants before 6 months old prevents allergies by over 80% (*LEAP, EAT). The trouble is that parents find it scary, inconvenient, and stressful to introduce a range allergens regularly to their infants. We have created a convenient set of organic fruit puree pouches that contain the same amounts of allergens as the breakthrough studies, making it easy and stress-free for parents to prevent allergies.

2017 Switzerland Gold Winner

Lymphatica is a medical device development company that has designed and patented LymphoDrain, a novel implantable system replacing lymphatic vessel draining function. The system is based on magnetically controlled micropumps, and it has been conceived to treat chronic lymphedema, a common side effect of cancer therapies. Currently there is no cure for lymphedema. LymphoDrain represents the first effective solution for more than 10 million lymphedema patients in EU and United States.

2015 Boston Gold Winner

LaunchPad Medical is developing Tetranite™, a bone adhesive that is gradually replaced by bone. Such a product has significant load-bearing strength and will provide a new tool for the surgeon to anchor metal implants, fill voids, and fix bone fragments back together while keeping procedures simpler, safer, and less expensive. Tetranite™ has a combination of strength, biocompatibility, and low cost to be commercially viable. The dental implant market will be the initial platform application.

2014 Boston Gold Winner

Annually 47 million people in the US fall victim to a water-borne infection. Current testing methods take 24 hours or more. This waiting time is too long for efficient quality control and to prevent disease outbreaks. Fluid-Screen brings the power of an entire lab into a portable device. Fluid-Screen detects bacteria in water in 30 minutes or less. The patent pending technology is based on a silicon biosensor chip developed at Yale University. We believe that Fluid-Screen will change the world.

2013 Boston Gold Winner

It is almost impossible to not know someone affected by breast cancer with 1 in 8 women diagnosed. The "Jacki" is a patent approved essential recovery garment that empowers cancer patients enduring extensive surgery. Its unique design increases mobility and independence, while reducing pain. Distributed by oncology network throughout 81 hospitals at the critical timing of diagnosis. This game-changing patient designed surgeon-endorsed garment is leveling the playing field in this unfair fight.

2012 Boston Gold Winner

90% of people 80+ want to live at home, but there can be risks. NTG health service has health sensors and software intelligence to detect abnormal patterns in behavior, allowing for early response. Our service detects serious issues -- even if someone is unconscious, has not fallen, or has not pressed an alarm. We help aging people maintain independent, active lives, and assure their families they are healthy and safe at home. We give aging people freedom, and their loved ones peace of mind.

2012 Boston Gold Winner

Lab Automate has developed and globally patented the A3G technology which can reduce the time to market of Inhalation products by up to 25%. The technology’s feasibility has been independently proven by tests done at Cirrus Pharmaceuticals and by University of Maryland. The technology has a $2.8 billion market which is growing @ 6%/annum. Expects to be profitable in 2nd year with 5th year sales projected @$50MM--is seeking $1.3MM to develop commercial scale equipment.

2012 Boston Gold Winner

Tooth loss affects nearly the entire adult population and significantly impacts quality of life. Dental implants are often the best treatment; however, it is hard to accurately drill a hole in the jaw to properly place an implant, and mistakes can be costly. We sell 3D image-based drill guides to help surgeons more easily and accurately place implants. Our patented guide solves the design issues of current guides, requires no investment (vs $5-10K), and is half the price of current guides.

2010 Boston Gold Winner

Energesis is a biotechnology company developing therapeutics for obesity and diabetes by targeting brown fat. Our approach is a highly novel strategy directed at increasing the bodys ability to burn stored fat. All previous attempts to combat obesity have focused on reducing energy intake, as opposed to Energesis' approach of increasing energy expenditure. Our management team brings a strong entrepreneurial record together with world-class scientific, medical, and product development expertise.

Sidecar Winners
2013 Boston Sidecar Winner

Today, stem cells derived from blood are very difficult to harvest. Current harvesting methods end up destroying the stem cells in the process. Quad Technologies has a game changing dissolvable hydrogel technology, QuickGel™, that selectively isolates stem cells from complex solutions while mitigating non-specific binding. QuickGel™ has applications in label-free cell separation, offline-sample prep, and IVD.

Silver Winners
2016 Israel Silver Winner

Access for Life's vision is to facilitate therapies that require repetitive vascular access (RVA) for chronic disease patients. Our patented JEM ™ devices technology & design will preserve the vessel wall & reduce clinical complications due to vessel wall damage e.g. perforation, pseudoaneurysms, hematomas, stenosis & thrombosis, reducing morbidity mortality& costs.
JEM: easier & safer RVA for hemodialysis & chemotherapy & continuous chronic intravenous infusion in adult & pediatric patients.

2015 UK Silver Winner

RE-VANA is working on new drug delivery systems that can provide significant long-term benefits for patients who are suffering from severe eye diseases that can lead to blindness. The new systems that we are developing will enhance patient comfort and improve their vision, which will eventually reduce the burden on healthcare services, patients and care givers.

2015 Boston Silver Winner

Pavlok: the first wearable that transforms your habits

Example: go to the gym by 10am.

Step 1: Accountability.

When you commit, you can’t remove Pavlok until you achieve your goal. It makes loud noises, or posts your fail to Facebook. Initially, it's your drill sergeant trainer. One model can even shock you with 1000 painful volts.

Step 2: Reinforcement

Pavlok adds positive reinforcement to make the habit stick, permanently.

Pavlok transforms you into a better you.

2014 Boston Silver Winner

Diagnostic of diseases is a 40 billion USD global market where current technologies are expensive, require specialized equipment and take several hours to produce results, affecting billions around the world mostly in developing countries. We developed a 5 minute and $1 diagnostic technology for infectious diseases that allows health data collection and analysis in real time for disease surveillance, using big data algorithms to help decision makers to create strategies for disease control.

2013 Boston Silver Winner

Every single drug discovered and every advance in modern medicine depends on laboratory mice. MouseHouse is an iPad + web application that allows researchers in the life-sciences to save time and money in managing lab mice. Its unique proprietary optimization software reduces colony size by 15% and it's the first tablet drag/drop based application that tracks experimental data, health and complex breeding schemes. Scientists from labs across the US--Harvard, Yale, Stanford, UCSF, UChi--are users

2012 Boston Silver Winner

WindGap Medical’s patient and clinician surveys show that the EpiPen® is bulky and awkward to carry, especially for children. It has tight temperature storage requirements of 68-77°F and will rapidly degrade outside of that range. Through patent-pending microfluidics and miniaturization, our product is as small as a USB drive, intuitive to use, and extends the storage temperature range out to 32-105°F. The market for our product is $1.05B, growing at 20% YoY.

2012 Boston Silver Winner

Cancer is diagnosed today much too late: increasing sensitivity by thousand folds, Akrivis’ Z-TECT technology will allow cancer detection so early that it will be cured faster and with less toxic drugs. Z-TECT can achieve this with blood tests or medical imaging of mm-sized tumors. After selling custom reagents to repeat customers for a year, Akrivis recently signed a worldwide distribution agreement and seeks $250k to hire 2 scientists and accelerate the launch of its first products by Q1 2013

2011 Boston Silver Winner

BIOARRAY Therapeutics is developing innovative molecular diagnostic tests that help women with breast cancer and their doctors identify more effective treatment sooner by predicting chemotherapy response across multiple cancer subtypes. Our test will help reduce the present "trial and error" approach to chemotherapy treatment decisions, helping patients while reducing overall treatment costs.

2011 Boston Silver Winner

ARO Medical is a spinal implant company reducing back pain in patients undergoing their first surgery and reducing the $3 billion associated with failed surgeries. The company۪s patent-pending, minimally-invasive device stabilizes the spine from excessive twisting, a source proven in NIH-sponsored research to be directly linked to back pain. It is used as an adjunct to existing surgery and has support of renowned spinal surgeons. Approvals have been obtained for an initial clinical trial.

2010 Boston Silver Winner

ViThera develops new drugs based on engineered beneficial bacteria. Our lead product VT201 targets IBD, such as Crohn's or Colitis, a significant unmet need, and addresses a $10bn/yr market. VT201 is a food strain bacterium (Lactococcus Lactis, typical component of cheese) engineered to express an anti-inflammatory protein which controls inflammation in the gut-after oral intake of the therapeutic bacteria. We have a uniquely experienced team and strong exclusive IP position.

2010 Boston Silver Winner

Biofilms, slimy communities of bacteria, cause biofouling, corrosion, energy inefficiency, diseases and $22B in annual costs. Current treatments are toxic, corrosive and environmentally damaging. We have developed a first-in-class anti-biofilm solution that is green and highly effective against biofilms. Our solution is enabled by expertise in synthetic and systems biology and can be combined with existing antimicrobials to eradicate industrial and environmental biofilms, a $2.2B market.

2010 Boston Silver Winner

Aukera Therapeutics is developing a novel protein therapy, to treat ALS (also known as Lou Gehrigs disease), a rare but devastating neurodegenerative disease that is rapidly progressive and invariably fatal, usually within 3-5 years. There is only one FDA approved drug for ALS which extends life only 2-3 months and has no effect on the symptoms of the disease. Replacement therapy with Angiogenin, has shown significant effect on both survival and motor function in ALS mice studies.

Startups
2017 Boston Gold Winner

W8X helps athletes get the most out of their workout. Inspired by robotics, we developed a training system that automatically changes resistance to adapt to a user's needs. The system has the size of a shoebox but provides safer and more effective training than traditional equipment. Controlled through an app, the system tracks metrics and provides valuable feedback. We work with leading coaches and professional athletes to reinvent strength training for the gym and for the home.
*fundraising

2017 Boston Gold Winner

Recent clinical studies proved that consistently introducing food allergens to infants before 6 months old prevents allergies by over 80% (*LEAP, EAT). The trouble is that parents find it scary, inconvenient, and stressful to introduce a range allergens regularly to their infants. We have created a convenient set of organic fruit puree pouches that contain the same amounts of allergens as the breakthrough studies, making it easy and stress-free for parents to prevent allergies.

2017 Switzerland Gold Winner

Lymphatica is a medical device development company that has designed and patented LymphoDrain, a novel implantable system replacing lymphatic vessel draining function. The system is based on magnetically controlled micropumps, and it has been conceived to treat chronic lymphedema, a common side effect of cancer therapies. Currently there is no cure for lymphedema. LymphoDrain represents the first effective solution for more than 10 million lymphedema patients in EU and United States.

2016 Israel Silver Winner

Access for Life's vision is to facilitate therapies that require repetitive vascular access (RVA) for chronic disease patients. Our patented JEM ™ devices technology & design will preserve the vessel wall & reduce clinical complications due to vessel wall damage e.g. perforation, pseudoaneurysms, hematomas, stenosis & thrombosis, reducing morbidity mortality& costs.
JEM: easier & safer RVA for hemodialysis & chemotherapy & continuous chronic intravenous infusion in adult & pediatric patients.

2015 UK Silver Winner

RE-VANA is working on new drug delivery systems that can provide significant long-term benefits for patients who are suffering from severe eye diseases that can lead to blindness. The new systems that we are developing will enhance patient comfort and improve their vision, which will eventually reduce the burden on healthcare services, patients and care givers.

2015 Boston Silver Winner

Pavlok: the first wearable that transforms your habits

Example: go to the gym by 10am.

Step 1: Accountability.

When you commit, you can’t remove Pavlok until you achieve your goal. It makes loud noises, or posts your fail to Facebook. Initially, it's your drill sergeant trainer. One model can even shock you with 1000 painful volts.

Step 2: Reinforcement

Pavlok adds positive reinforcement to make the habit stick, permanently.

Pavlok transforms you into a better you.

2015 Boston Gold Winner

LaunchPad Medical is developing Tetranite™, a bone adhesive that is gradually replaced by bone. Such a product has significant load-bearing strength and will provide a new tool for the surgeon to anchor metal implants, fill voids, and fix bone fragments back together while keeping procedures simpler, safer, and less expensive. Tetranite™ has a combination of strength, biocompatibility, and low cost to be commercially viable. The dental implant market will be the initial platform application.

2014 Boston Silver Winner

Diagnostic of diseases is a 40 billion USD global market where current technologies are expensive, require specialized equipment and take several hours to produce results, affecting billions around the world mostly in developing countries. We developed a 5 minute and $1 diagnostic technology for infectious diseases that allows health data collection and analysis in real time for disease surveillance, using big data algorithms to help decision makers to create strategies for disease control.

2014 Boston Diamond Winner

SQZ Biotech’s CellSqueeze enables the delivery of molecules into cells by a gentle squeezing. It was invented at MIT in the labs of Prof. Bob Langer and Prof. Klavs Jensen. It's shown 10-100x improvement relative to competing technologies for major unmet needs: primary cells and non-nucleid acid molecules (e.g. proteins). We own the exclusive license from MIT to any application. We started in the research market but plan to pursue higher impact applications (e.g. therapeutics) in the future.

2014 Boston Gold Winner

Annually 47 million people in the US fall victim to a water-borne infection. Current testing methods take 24 hours or more. This waiting time is too long for efficient quality control and to prevent disease outbreaks. Fluid-Screen brings the power of an entire lab into a portable device. Fluid-Screen detects bacteria in water in 30 minutes or less. The patent pending technology is based on a silicon biosensor chip developed at Yale University. We believe that Fluid-Screen will change the world.

2013 Boston Sidecar Winner

Today, stem cells derived from blood are very difficult to harvest. Current harvesting methods end up destroying the stem cells in the process. Quad Technologies has a game changing dissolvable hydrogel technology, QuickGel™, that selectively isolates stem cells from complex solutions while mitigating non-specific binding. QuickGel™ has applications in label-free cell separation, offline-sample prep, and IVD.

2013 Boston Silver Winner

Every single drug discovered and every advance in modern medicine depends on laboratory mice. MouseHouse is an iPad + web application that allows researchers in the life-sciences to save time and money in managing lab mice. Its unique proprietary optimization software reduces colony size by 15% and it's the first tablet drag/drop based application that tracks experimental data, health and complex breeding schemes. Scientists from labs across the US--Harvard, Yale, Stanford, UCSF, UChi--are users

2013 Boston Gold Winner

It is almost impossible to not know someone affected by breast cancer with 1 in 8 women diagnosed. The "Jacki" is a patent approved essential recovery garment that empowers cancer patients enduring extensive surgery. Its unique design increases mobility and independence, while reducing pain. Distributed by oncology network throughout 81 hospitals at the critical timing of diagnosis. This game-changing patient designed surgeon-endorsed garment is leveling the playing field in this unfair fight.

2012 Boston Silver Winner

WindGap Medical’s patient and clinician surveys show that the EpiPen® is bulky and awkward to carry, especially for children. It has tight temperature storage requirements of 68-77°F and will rapidly degrade outside of that range. Through patent-pending microfluidics and miniaturization, our product is as small as a USB drive, intuitive to use, and extends the storage temperature range out to 32-105°F. The market for our product is $1.05B, growing at 20% YoY.

2012 Boston Gold Winner

90% of people 80+ want to live at home, but there can be risks. NTG health service has health sensors and software intelligence to detect abnormal patterns in behavior, allowing for early response. Our service detects serious issues -- even if someone is unconscious, has not fallen, or has not pressed an alarm. We help aging people maintain independent, active lives, and assure their families they are healthy and safe at home. We give aging people freedom, and their loved ones peace of mind.

2012 Boston Gold Winner

Lab Automate has developed and globally patented the A3G technology which can reduce the time to market of Inhalation products by up to 25%. The technology’s feasibility has been independently proven by tests done at Cirrus Pharmaceuticals and by University of Maryland. The technology has a $2.8 billion market which is growing @ 6%/annum. Expects to be profitable in 2nd year with 5th year sales projected @$50MM--is seeking $1.3MM to develop commercial scale equipment.

2012 Boston Gold Winner

Tooth loss affects nearly the entire adult population and significantly impacts quality of life. Dental implants are often the best treatment; however, it is hard to accurately drill a hole in the jaw to properly place an implant, and mistakes can be costly. We sell 3D image-based drill guides to help surgeons more easily and accurately place implants. Our patented guide solves the design issues of current guides, requires no investment (vs $5-10K), and is half the price of current guides.

2012 Boston Silver Winner

Cancer is diagnosed today much too late: increasing sensitivity by thousand folds, Akrivis’ Z-TECT technology will allow cancer detection so early that it will be cured faster and with less toxic drugs. Z-TECT can achieve this with blood tests or medical imaging of mm-sized tumors. After selling custom reagents to repeat customers for a year, Akrivis recently signed a worldwide distribution agreement and seeks $250k to hire 2 scientists and accelerate the launch of its first products by Q1 2013

2011 Boston Silver Winner

BIOARRAY Therapeutics is developing innovative molecular diagnostic tests that help women with breast cancer and their doctors identify more effective treatment sooner by predicting chemotherapy response across multiple cancer subtypes. Our test will help reduce the present "trial and error" approach to chemotherapy treatment decisions, helping patients while reducing overall treatment costs.

2011 Boston Silver Winner

ARO Medical is a spinal implant company reducing back pain in patients undergoing their first surgery and reducing the $3 billion associated with failed surgeries. The company۪s patent-pending, minimally-invasive device stabilizes the spine from excessive twisting, a source proven in NIH-sponsored research to be directly linked to back pain. It is used as an adjunct to existing surgery and has support of renowned spinal surgeons. Approvals have been obtained for an initial clinical trial.

2010 Boston Silver Winner

ViThera develops new drugs based on engineered beneficial bacteria. Our lead product VT201 targets IBD, such as Crohn's or Colitis, a significant unmet need, and addresses a $10bn/yr market. VT201 is a food strain bacterium (Lactococcus Lactis, typical component of cheese) engineered to express an anti-inflammatory protein which controls inflammation in the gut-after oral intake of the therapeutic bacteria. We have a uniquely experienced team and strong exclusive IP position.

2010 Boston Silver Winner

Biofilms, slimy communities of bacteria, cause biofouling, corrosion, energy inefficiency, diseases and $22B in annual costs. Current treatments are toxic, corrosive and environmentally damaging. We have developed a first-in-class anti-biofilm solution that is green and highly effective against biofilms. Our solution is enabled by expertise in synthetic and systems biology and can be combined with existing antimicrobials to eradicate industrial and environmental biofilms, a $2.2B market.

2010 Boston Gold Winner

Energesis is a biotechnology company developing therapeutics for obesity and diabetes by targeting brown fat. Our approach is a highly novel strategy directed at increasing the bodys ability to burn stored fat. All previous attempts to combat obesity have focused on reducing energy intake, as opposed to Energesis' approach of increasing energy expenditure. Our management team brings a strong entrepreneurial record together with world-class scientific, medical, and product development expertise.

2010 Boston Silver Winner

Aukera Therapeutics is developing a novel protein therapy, to treat ALS (also known as Lou Gehrigs disease), a rare but devastating neurodegenerative disease that is rapidly progressive and invariably fatal, usually within 3-5 years. There is only one FDA approved drug for ALS which extends life only 2-3 months and has no effect on the symptoms of the disease. Replacement therapy with Angiogenin, has shown significant effect on both survival and motor function in ALS mice studies.